Oral GLP-1 RA peptide program clinical trial initiated Metsera has initiated a clinical trial ... and candidates targeting other complementary NuSH pathways, including glucagon and PYY, as well as ...
DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, DA-1241 demonstrated a positive effect on ...
GLP-1 medications like Ozempic and Wegovy are sprinting their way into the fitness community, changing how athletes approach training, nutrition, and performance. Here’s what’s really going ...
Natural body mass homeostasis is best achieved by eating a diet rich in plant-derived fibre, and low in saturated fats and highly processed carbohydrates.
Innovent Biologics is planning a second filing for its dual GLP-1/glucagon agonist mazdutide in China, as it tries to carve out a share of a market currently dominated by Novo Nordisk and Eli Lilly.
The first GLP-1 medication was prescribed beginning in 2006, and the authors included cases beginning in 2000 to increase the power of the study, they noted. Note: The study featured in this news ...
A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the progression of Parkinson’s disease, pointing to another potential use for the fast-growing drug ...
Today, we talk a whole lot about RFK Jr., and also President-elect Donald Trump. Plus, we note that GLP-1 drugs can increase a person’s risk of aspiration when undergoing surgery. Have a nice week!